{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:36:19Z","timestamp":1767846979096,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1111\/1469-0691.12444","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T09:38:47Z","timestamp":1387445927000},"page":"76-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"S5","title":["Hexavalent vaccines for immunization in paediatric age"],"prefix":"10.1016","volume":"20","author":[{"given":"S.","family":"Esposito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tagliabue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bosis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ierardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gambino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Principi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/1469-0691.12444_bib1","author":"Centers for Disease Prevention and Control"},{"key":"10.1111\/1469-0691.12444_bib2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.pedhc.2007.09.004","article-title":"Societal impact of combination vaccines: experiences of physicians, nurses, and parents","volume":"22","author":"Koslap-Petraco","year":"2008","journal-title":"J Pediatr Health Care"},{"key":"10.1111\/1469-0691.12444_bib3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/archfami.3.7.610","article-title":"Too many shots? Parent, nurse, and physician attitudes toward multiple simultaneous childhood vaccinations","volume":"3","author":"Madlon-Kay","year":"1994","journal-title":"Arch Fam Med"},{"key":"10.1111\/1469-0691.12444_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archfami.3.7.615","article-title":"Multiple immunizations: ouch!","volume":"3","author":"Melman","year":"1994","journal-title":"Arch Fam Med"},{"key":"10.1111\/1469-0691.12444_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1542\/peds.96.5.889","article-title":"Beliefs and practices regarding childhood vaccination among urban pediatric providers in New Jersey","volume":"96","author":"Askew","year":"1995","journal-title":"Pediatrics"},{"key":"10.1111\/1469-0691.12444_bib6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archpedi.1995.02170210019003","article-title":"Physician and parent opinions: are children becoming pincushions from immunizations?","volume":"149","author":"Woodin","year":"1995","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1111\/1469-0691.12444_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0749-3797(18)30204-6","article-title":"Barriers to measles and pertussis immunization: the knowledge and attitudes of Pennsylvania primary care physicians","volume":"13","author":"Zimmerman","year":"1997","journal-title":"Am J Prev Med"},{"key":"10.1111\/1469-0691.12444_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/archpedi.152.1.12","article-title":"Physician concerns about vaccine side effects and potential litigation","volume":"152","author":"Zimmerman","year":"1998","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1111\/1469-0691.12444_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archpedi.152.3.285","article-title":"Vaccine-associated liability risk and provider immunization practices","volume":"152","author":"Freed","year":"1998","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"Suppl 4","key":"10.1111\/1469-0691.12444_bib10","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1086\/322571","article-title":"Considerations for combination vaccine development and use in the developing world","volume":"33","author":"Di Fabio","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"RR-5","key":"10.1111\/1469-0691.12444_bib11","first-page":"1","article-title":"Combination vaccines for childhood immunization recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the AmericanAcademy of Family Physicians (AAFP)","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"MMWR"},{"key":"10.1111\/1469-0691.12444_bib12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.vaccine.2003.09.039","article-title":"A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b and hepatitis B: review of immunogenicity and safety","volume":"22","author":"Mallet","year":"2004","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib13","author":"European Medicines Agency"},{"key":"10.1111\/1469-0691.12444_bib14","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1017\/S0950268810000543","article-title":"Low hepatitis B immunogenicity of a hexavalent vaccine widely used in Germany: results of the German Health Survey for Children and Adolescents, 2003\u20132006","volume":"138","author":"Jorgensen","year":"2010","journal-title":"Epidemiol Infect"},{"key":"10.1111\/1469-0691.12444_bib16","author":"European Medicines Agency"},{"key":"10.1111\/1469-0691.12444_bib17","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.vaccine.2007.11.096","article-title":"Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants","volume":"26","author":"Olivier","year":"2008","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib18","first-page":"678","article-title":"Notification to health experts, 20 September 2005: Swissmedic suspends the license of Hexavac vaccine","volume":"9","author":"Swissmedic","year":"2005","journal-title":"Swissmedic J"},{"key":"10.1111\/1469-0691.12444_bib19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S1473-3099(10)70195-X","article-title":"Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study","volume":"10","author":"Zanetti","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/1469-0691.12444_bib20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1471-2334-8-100","article-title":"A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines","volume":"8","author":"Giambi","year":"2008","journal-title":"BMC Infect Dis"},{"key":"10.1111\/1469-0691.12444_bib21","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.1016\/j.vaccine.2012.06.078","article-title":"Challenge with a hepatitis B vaccine in two cohorts of 4\u20137-year-old children primed with hexavalent vaccines: an open-label, randomised trial in Italy","volume":"30","author":"Zanetti","year":"2012","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/INF.0b013e31827bd1b0","article-title":"Determinants of long-term protection after hepatitis B vaccination in infancy: a meta-analysis","volume":"32","author":"Sch\u00f6nberger","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/1469-0691.12444_bib23","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1016\/j.vaccine.2007.09.013","article-title":"Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination","volume":"25","author":"Su","year":"2007","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib24","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1086\/587695","article-title":"Humoral and cellular immune responses to a hepatitis B vaccine booster 15\u201318 years after neonatal immunization","volume":"197","author":"Lu","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1111\/1469-0691.12444_bib25","article-title":"Chronic hepatitis B infection in adolescents vaccinated at birth: an alarm bell in favor of the need for a booster?","author":"Roman\u00f2","year":"2013","journal-title":"Hepatology"},{"key":"10.1111\/1469-0691.12444_bib26","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.vaccine.2011.01.025","article-title":"Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo controlled trial cohort from China where endemicity is high","volume":"29","author":"Wu","year":"2011","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00431-004-1594-7","article-title":"Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilius influenzae type b): is there a signal?","volume":"164","author":"von Kries","year":"2005","journal-title":"Eur J Pediatr"},{"key":"10.1111\/1469-0691.12444_bib28","doi-asserted-by":"crossref","first-page":"e16363","DOI":"10.1371\/journal.pone.0016363","article-title":"Sudden unexpected deaths and vaccinations during the first two years of life in Italy: a case series study","volume":"6","author":"Traversa","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1111\/1469-0691.12444_bib29","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/11204830-000000000-00000","article-title":"DTPa-HBV-IPV\/Hib vaccine (Infanrix hexa): a review of its use as primary and booster vaccination","volume":"70","author":"Dhillon","year":"2010","journal-title":"Drugs"},{"key":"10.1111\/1469-0691.12444_bib30","first-page":"445","article-title":"WHO position paper on Haemophilus influenzae type b conjugate vaccines","volume":"81","author":"World Health Organization","year":"2006","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1111\/1469-0691.12444_bib31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1067\/mpd.2000.107796","article-title":"Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections","volume":"137","author":"Schmitt","year":"2000","journal-title":"J Pediatr"},{"key":"10.1111\/1469-0691.12444_bib32","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1016\/S0264-410X(03)00420-1","volume":"21","author":"Ar\u00edstegui","year":"2003","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib33","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/j.vaccine.2003.11.044","article-title":"Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants","volume":"22","author":"Zepp","year":"2004","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00431-002-1079-5","article-title":"Immunogenicity and reactogenicity of a novel hexavalent DTPa-HB-V-IPV\/Hib vaccine compared to separate concomitant injections of DTPa-IPV\/Hib and HBV vaccines when administered according to a 3, 5 and 11 month vaccination schedule","volume":"161","author":"Avdicova","year":"2002","journal-title":"Eur J Pediatr"},{"key":"10.1111\/1469-0691.12444_bib35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/00365540410017572","article-title":"Evaluation of the immunogenicity and reactogenicity of a DTPa-HB-V-IPV combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age","volume":"36","author":"Gabutti","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"10.1111\/1469-0691.12444_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4161\/hv.2.6.3432","article-title":"Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccines and evaluation of booster vaccination","volume":"2","author":"Tichmann","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.1111\/1469-0691.12444_bib37","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.vaccine.2006.09.060","volume":"25","author":"Heininger","year":"2007","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib38","doi-asserted-by":"crossref","first-page":"801","DOI":"10.47102\/annals-acadmedsg.V36N10p801","article-title":"Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine","volume":"36","author":"Lim","year":"2007","journal-title":"Ann Acad Med Singapore"},{"key":"10.1111\/1469-0691.12444_bib39","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/00006454-200209000-00014","article-title":"Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination","volume":"21","author":"Pichichero","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/1469-0691.12444_bib40","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1542\/peds.2004-2336","article-title":"Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue","volume":"116","author":"Ome\u00f1aca","year":"2005","journal-title":"Pediatrics"},{"key":"10.1111\/1469-0691.12444_bib41","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/INF.0b013e318124a9c8","article-title":"Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely","volume":"26","author":"Ome\u00f1aca","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/1469-0691.12444_bib42","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1542\/peds.2005-2907","article-title":"Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus\/Haemophilus influenzae type b vaccine","volume":"119","author":"Ome\u00f1aca","year":"2007","journal-title":"Pediatrics"},{"key":"10.1111\/1469-0691.12444_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.inf.0000148923.46453.48","article-title":"Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate conjugate vaccine","volume":"24","author":"Tichmann-Schumann","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/1469-0691.12444_bib44","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1016\/j.vaccine.2006.03.032","article-title":"Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV\/Hib combination vaccine in healthy infants","volume":"29","author":"Knuf","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl. 4","key":"10.1111\/1469-0691.12444_bib45","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/INF.0b013e318199f61b","article-title":"Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)","volume":"28","author":"Knuf","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/1469-0691.12444_bib46","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.1016\/j.vaccine.2011.06.026","volume":"29","author":"Gimenez-Sanchez","year":"2011","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib47","doi-asserted-by":"crossref","first-page":"743","DOI":"10.4161\/hv.19642","article-title":"Immunogenicity of a hexavalent vaccine co-administered with 7-valent pneumococcal conjugate vaccine. Findings from the National Immunisation Programme in The Netherlands","volume":"8","author":"Whelan","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1111\/1469-0691.12444_bib48","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/01.inf.0000227725.61495.c4","volume":"25","author":"Tejedor","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/1469-0691.12444_bib49","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/01.inf.0000145427.19167.35","article-title":"Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine","volume":"23","author":"Tejedor","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/1469-0691.12444_bib50","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix\u2122 hexa is immunogenic, with an acceptable safety profile in 12\u201323-month-old children","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib51","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00431-007-0506-z","volume":"166","author":"Zepp","year":"2007","journal-title":"Eur J Pediatr"},{"key":"10.1111\/1469-0691.12444_bib52","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1016\/j.vaccine.2010.05.057","article-title":"Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe","volume":"28","author":"Vesikari","year":"2010","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4161\/hv.6.2.10117","article-title":"Immunological persistence in 4\u20136 and 7\u20139 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV\/Hib","volume":"6","author":"Zinke","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1111\/1469-0691.12444_bib54","doi-asserted-by":"crossref","first-page":"592","DOI":"10.4161\/hv.9051","article-title":"Immune memory to hepatitis B virus in 4\u20139-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV\/Hib vaccine","volume":"5","author":"Zinke","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1111\/1469-0691.12444_bib55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2334-10-9","article-title":"Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV\/Hib in the first and 2nd year of life","volume":"10","author":"Steiner","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1111\/1469-0691.12444_bib56","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.vaccine.2004.08.030","article-title":"Booster vaccination with hexavalent DTPa-HBV-IPV\/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV\/Hib + HBV administered separately","volume":"23","author":"Saenger","year":"2005","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.1996.03530250041024","article-title":"Efficacy of acellular pertussis vaccine in early childhood after household exposure","volume":"275","author":"Schmitt","year":"1996","journal-title":"JAMA"},{"key":"10.1111\/1469-0691.12444_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM199602083340601","article-title":"A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group","volume":"334","author":"Greco","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/1469-0691.12444_bib59","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1542\/peds.2005-2746","article-title":"Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age","volume":"118","author":"Gustafsson","year":"2006","journal-title":"Pediatrics"},{"key":"10.1111\/1469-0691.12444_bib60","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1586\/erv.09.32","article-title":"Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV\/Hib hexavalent vaccine)","volume":"8","author":"Zepp","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1111\/1469-0691.12444_bib61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40272-013-0007-7","article-title":"DTaP-IPV-Hep B-Hib vaccine (Hexaxim\u00ae): a review of its use in primary and booster vaccination","volume":"15","author":"McCormack","year":"2013","journal-title":"Paediatr Drugs"},{"key":"10.1111\/1469-0691.12444_bib62","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/14712598.2013.774368","article-title":"Review of a new fully liquid, hexavalent vaccine: Hexaxim","volume":"13","author":"Nunes","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/1469-0691.12444_bib63","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/INF.0b013e31820b93d2","article-title":"Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants","volume":"30","author":"Madhi","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/1469-0691.12444_bib64","unstructured":"Ceyhan M, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent fully liquid DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim\u00ae) given at 2, 3, 4 months of age and as a booster at 15\u201318 months compared to licensed vaccines in Turkish infants. 5th Asian Congress of Pediatric Infectious Diseases; 23\u201326 September 2010; Taipei, Taiwan."},{"key":"10.1111\/1469-0691.12444_bib65","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1097\/INF.0b013e318212eb80","article-title":"Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants","volume":"30","author":"Tregnaghi","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/1469-0691.12444_bib66","doi-asserted-by":"crossref","unstructured":"Lopez P, Arguedas A, Consuelo-Miranda M. Immunogenicity and safety of a primary series of a new fully liquid DTaO-IPV-HepB-PRP-T hexavalent vaccine (Hexaxim\u2122) co-administered with Prevenar\u2122 and Rotarix in healthy children in America Latina. Presented at 15th International Congress of Infectious Diseases, 13\u201316 Lune 2012, Bangkok, Thailand.","DOI":"10.1016\/j.ijid.2012.05.1012"},{"key":"10.1111\/1469-0691.12444_bib67","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1016\/j.vaccine.2012.07.040","article-title":"A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children","volume":"30","author":"Aquino","year":"2012","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12444_bib68","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/INF.0b013e318258400d","article-title":"Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America","volume":"31","author":"Mac\u00edas","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/1469-0691.12444_bib69","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.ijid.2010.12.004","volume":"15","author":"Kosalaraksa","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1111\/1469-0691.12444_bib70","unstructured":"Madhi SA, Mitha I, Koen A. Post primary persistence and immunogeni city\/safety of an investigational DRaP-IPV-Hep B-PRP-T (Hexaxim\u2122) booster vaccine compared to licensed vaccines in South Africa. 7th Congress of the World Society for Pediatric Infectious Diseases (WSPID); 16\u201319 November 2011; Melbourne, Australia."},{"key":"10.1111\/1469-0691.12444_bib71","first-page":"100","article-title":"Immunogenicity and safety of a fully liquid DTaP-IPV-Hep B-vaccine at 2\u20134\u20136 months of age in Peru","volume":"3","author":"Lanata","year":"2012","journal-title":"J Vaccines"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14601798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14601798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:12:17Z","timestamp":1761117137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14601798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":70,"alternative-id":["S1198743X14601798"],"URL":"https:\/\/doi.org\/10.1111\/1469-0691.12444","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hexavalent vaccines for immunization in paediatric age","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/1469-0691.12444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}